BioSpace News Archive

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced that it is has filed for a trademark for RLF-100TM with the United States Patent and Trademark Office.

Photocure ASA, The Bladder Cancer Company, announces that President and Chief Executive Officer, Dan Schneider and Chief Financial Officer, Erik Dahl will present a corporate overview and host 1-on-1 meetings with investors at the 11th Annual SVB Leerink Global Healthcare Conference, being held virtually February 14-18, 2022.

Diaccurate, a French biotech company that develops sole-in-class drug candidates in oncology and immunotherapy, announced the appointment of Laurence Riot Lamotte as Chief Financial Officer, effective January 3, 2022.

The life science group Sartorius announced that, through its subgroup Sartorius Stedim Biotech, it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission.

Exact Sciences Corp., a leader in advanced cancer diagnostics, announced that the company plans to release its fourth quarter 2021 financial results after the close of the U.S. financial markets on February 22, 2022.

Alzheon, Inc. reported a clinically relevant and statistically significant plasma biomarker reduction and memory improvement in Alzheimer’s patients following 6 months of treatment with oral tablet ALZ-801 in its Phase 2 biomarker trial.

Centene Corporation announced its financial results for the fourth quarter and year ended December 31, 2021, reporting diluted earnings per share of $1.01 and $2.28, respectively, and adjusted diluted EPS of $1.01 and $5.15, respectively.

AlzeCure Pharma AB announced that it has received a response from the US Food and Drug Administration regarding the preIND application that was submitted prior to the planned phase IIa study with ACD440 in neuropathic pain.

Immunic, Inc. today announced participation in the following investor and scientific conferences in February.

EdiGene, Inc. announced a non-exclusive, worldwide license agreement with Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, to access Arbor’s proprietary CRISPR gene editing technology for certain ex vivo engineered cell therapy programs in the field of oncology.